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Abstract
Background: Chagas disease (CD) is endemic in Central and South America, Mexico and even in some areas of the United
States. However, cases have been increasingly recorded also in non-endemic countries. The estimated number of infected
people in Europe is in a wide range of 14000 to 181000 subjects, mostly resident in Spain, Italy and the United Kingdom.
Methodology/Principal Findings: Retrospective, observational study describing the characteristics of patients with CD who
attended the Centre for Tropical Diseases (Negrar, Verona, Italy) between 2005 and 2013. All the patients affected by CD
underwent chest X-ray, ECG, echocardiography, barium X-ray of the oesophagus and colonic enema. They were classified in
the indeterminate, cardiac, digestive or mixed category according to the results of the screening tests. Treatment with
benznidazole (or nifurtimox in case of intolerance to the first line therapy) was offered to all patients, excluding the ones
with advanced cardiomiopathy, pregnant and lactating women. Patients included were 332 (73.9% women). We classified
68.1% of patients as having Indeterminate Chagas, 11.1% Cardiac Chagas, 18.7% as Digestive Chagas and 2.1% as Mixed
Form. Three hundred and twenty-one patients (96.7%) were treated with benznidazole, and most of them (83.2%)
completed the treatment. At least one adverse effect was reported by 27.7% of patients, but they were mostly mild. Only a
couple of patients received nifurtimox as second line treatment.
Conclusions/Significance: Our case series represents the largest cohort of T. cruzi infected patients diagnosed and treated
in Italy. An improvement of the access to diagnosis and cure is still needed, considering that about 9200 infected people are
estimated to live in Italy. In general, there is an urgent need of common guidelines to better classify and manage patients
with CD in non-endemic countries.
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Introduction
Chagas disease (CD) is a protozoan zoonosis caused by
Trypanosoma cruzi (T.cruzi), with a widespread distribution from
the South of the United States to Mexico, Central and South
America [1]. Current data indicate that between 7 and 8 million
people are infected in this area [2]. Other authors suppose that in
North America (Canada, USA, Mexico) there might be many
more infected subjects than it was previously estimated (1 to 6
million people) [3], therefore global estimations should be revised.
In endemic countries, T. cruzi infection is usually transmitted
through contact with faeces of blood-sucking triatomines, rarely
after oral ingestion of food contaminated by triatomines faeces.
Other non-vectorial routes of transmission are transplacentary,
blood transfusion and organ/tissue transplantation [1].
The acute stage of the infection is frequently asymptomatic
(95% of cases); when symptomatic, acute CD can cause
myocarditis and encephalomyelitis with reported 5–10% mortality
[1]. If not treated, the acute phase is followed by a chronic stage,
corresponding to an indeterminate form, lasting long-life in
around 60–70% of patients. During this phase patients are
clinically silent: however, after 10 to 30 years, around 30–40% of
infected people will develop symptomatic chronic CD, which is
mainly characterized by cardiac and gastrointestinal disorders [1].
As a consequence of migration flows, the disease has been
increasingly recorded also in non-endemic countries and is
becoming a global health problem [4]. The estimated number of
infected people in Europe is in a wide range of 14,000 to 181,000
subjects [5]. Italy has a large number of residents of Latin
American origin, second in Europe only to Spain [6]. Strasen et al
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estimate that in Italy there are about 9,200 cases (range 1,400–
17,000) [5].
The majority of Latin American migrants reached Italy in the
past ten years, with a growing trend. Migrants from different
countries tend to have a patchy distribution in Italian Regions,
with a major concentration in Northern Italy and in Rome. For
instance most Bolivians live in Bergamo Province, Lombardy,
Ecuadorians in Liguria Region, and Peruvians in big cities such as
Milan, Florence and Rome [6].
The Centre for Tropical Diseases (CTD), Hospital Sacro Cuore
(Negrar, Verona) contributed to describe this new epidemiological
scenario and became a reference center in the management of
CD.
Aim of this paper is to describe the characteristics of patients
with CD attended at our center.
Methods
Study design
This is a retrospective, observational study, including all patients
with CD attended at CTD between 2005 and 2013. Most of these
patients were identified through a specific screening programme
offered by our center to Latin American communities resident in
Northern Italy; moreover, other patients were referred from other
centers to the CTD on the basis of clinical suspicion. Up to 2014,
there were no other screening programmes in Italy focused on
CD.
Information collected included clinical and epidemiological
characteristics such as: age, gender, country of origin, history of
living in rural environments and mud houses, time since arrival to
our country, history of blood transfusion in endemic countries, co-
morbidities causing immunosuppression, cardiac and gastrointes-
tinal assessment, completion of treatment. Data were anonymized
and entered in an Epi-Info database.
Chagas Disease diagnosis was based on two concordant positive
serological tests, using different antigens, a recombinant antigen-
based ELISA (BioELISA Chagas, Biokit, Llic¸a d9Almunt, Spain)
plus either a T.cruzi lysate antigen-based ELISA (BioELISA
Chagas III, BiosChile, Santiago, Chile) or an immunochromato-
graphic assay (Chagas Quick Test, Cypress Diagnostics, Belgium).
As recommended by the World Health Organization [7], in case
of discordant result, a third assay (an immunoblot, TESA-cruzi)
[8] was performed. Patients with CD were examined following an
internal protocol that included haematology and biochemistry.
Cardiac involvement was assessed with chest X-ray, electrocar-
diogram (ECG), echocardiography [9]. Chest X-ray was consid-
ered pathological in case of cardiac enlargement, defined as
cardiothoracic ratio greater than 0,5. The ECG was evaluated by
a cardiologist and considered pathological in case of bradycardia
,50 bpm, atrio-ventricular block, bundle branch block or
hemiblock, low voltages, tachyarrhythmia of any origin, Q-waves
suggestive of necrosis and T-waves changes suggesting ischemia.
The echocardiography was considered pathological in case of
systolic dysfunction, defined as a left ventricular ejection fraction
(LVEF) below 45%, segmental abnormalities of myocardial
contraction, presence of aneurismas (typically apical), dilated
cardiomyopathy [9].
The modified Brazilian classification was followed for cardiac
CD classification [10].
Digestive involvement was assessed with barium X-ray of the
oesophagus (oesophagogram) [11] and colonic enema [12].
Oesophagogram was considered pathological following Re-
zende’s classification [11].
Barium enema was defined pathological in case of megacolon
(descending colon diameter.6,5 cm or ascending colon diame-
ter.8 cm, or caecum diameter.12 cm) [13] or dolichocolon
(length from the anus to the transition to the descending colon.
70 cm) [13].
T. cruzi infected patients without cardiac or digestive involve-
ment were classified as Chagas indeterminate form; patients with
cardiac or digestive involvement were classified respectively as
Chagas cardiac form or Chagas digestive form, while patients with
both cardiac and digestive form were classified as Chagas mixed
form.
Specific treatment with benznidazole at 5 mg/kg/day divided
into three daily doses for 60 days was offered to all infected
patients, after careful explanation of benefits and risks of the
therapy. Although current guidelines [14] recommend to offer the
treatment to patients under 50 years of age, we extended the age
limit up to 60 year-old patients, in the absence of severe
comorbidities. Patients with advanced cardiomyopathy, pregnant
(pregnancy test was performed in all women of child-bearing age
before treatment) and lactating women were excluded. In patients
weighing more than 60 kg, a fixed daily dose of 300 mg was given
for a total number of days equal to the patient’s weight in
kilograms, resulting in a total dose that is equivalent to 5 mg/kg
per day for sixty days [15]. In case of important early side effects
due to benznidazole, nifurtimox (10 mg/kg/day for 60 days) was
prescribed. Patients were considered adequately treated when the
drug was taken for at least one month [16]. In case of mild adverse
effects, continuation of treatment was encouraged, while benzni-
dazole was stopped in case of severe adverse effects: for instance,
severe allergic skin reactions, peripheral neuropathy, leucopoenia
(WBC ,2500 cells/mL).
Patients underwent a blood test (cell blood count and general
biochemistry) at the beginning of the treatment and after 21 days.
At day 30 they came for follow up visit to our outpatient clinic: if
no significant laboratory or clinical adverse events were recorded,
the remaining tablets were given to the patient for the completion
of treatment. During the second month of treatment, follow-up
was done through phone call or visit according to physician’s
judgement. We assessed the adherence to the treatment on the
basis of what the patients reported during the phone calls/visits.
Pregnant and lactating women found positive at the screening
test for CD were followed up in a different way, because they could
not undergo all the diagnostic examinations needed to evaluate a
possible cardiac/intestinal involvement (barium enema and chest
X ray for instance) and could not take the treatment. Therefore,
their data were included in this analysis only once they could
complete the staging and receive the therapy (that is after they
stopped to breastfeed).
Author Summary
Chagas disease is endemic in Central and South America,
Mexico and part of the United States. However, migration
flows permitted a diffusion outside those borders, so
nowadays there are infected people living in Europe,
mostly in Spain, Italy and the United Kingdom. This
manuscript describes the patients with Chagas disease
attended at a referral center in Italy between 2005 and
2013. They were classified into different categories
according to the presence of possible cardiac and/or
gastrointestinal involvement: one third of patients pre-
sented signs of organ damage. Ninety-seven percent of
the infected patients were treated with benznidazole, 16%
had to stop the treatment due to adverse events.
Chagas Disease in Italy
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Statistical analysis
Data were analysed with Epi-Info program, version 7.1.0.6,
Centers for Disease Control, August, 2012. Chi-squared test was
used for dichotomous variables and t-test for continuous variables,
as appropriate.
Ethical issues
Written informed consent was required from the patients at the
moment of the execution of the screening test. The study protocol
was approved by the Ethics Committee (Comitato Etico della
Provincia di Verona) on February 19th 2013.
Results
During the 9–year period, 332 patients were included in this
study. Characteristics of the patients are described in table 1. The
majority of the patients were women (73.9%) and the mean age
was 41.8 years (range 11–71). Sixty-one per cent of the patients
reported living in rural areas and 73.2% in mud houses, while
6.9% of them reported history of blood transfusion in endemic
countries. Ninety-seven percent of the patients came from rural
high-prevalence Bolivian environments, especially from Santa
Cruz and Cochabamba Departments.
Four patients were under immunosuppressant therapies: two for
rheumatoid arthritis, one for psoriasis, one for systemic lupus
erithematosus (SLE). One patient had acquired immunodeficiency
syndrome (AIDS).
According to the findings of instrumental exams, 226 (68.1%)
subjects were classified as Indeterminate Chagas, 37 (11.1%) as
Cardiac Chagas, 62 (18.7%) as Digestive Chagas, 7 (2.1%) as
Mixed Form (Fig. 1).
Cardiac involvement is reported in table 2. In 288 patients
(86.8%) ECG and echocardiogram resulted normal. Among
patients with abnormal findings, the majority were classified in
stage A (9%) or B1 (2%) (table 3 shows the ECG alterations
found). The patient with AIDS showed abnormal ECG findings,
abnormal echocardiogram findings with refractory CHF and
needed cardiac transplantation. Four patients already had
pacemaker at the time of diagnosis, while two needed pacemaker
implantation at the time of the diagnosis or during the follow –up.
Gastrointestinal involvement is reported in table 4. At barium
enema, dolichocolon was found in 33 patients (9.9%) and
megacolon in 30 patients (9.0%). Oesophagogram resulted slightly
pathological (group I) in 3 patients (0.9%). No patient was
classified in group II and III. One patient was classified in group
IV, because he underwent surgery for dolicho-megaoesophagus in
Bolivia. One patient underwent multiple operations because of
colonic volvulus. Two other patients presented mega-colon
without toxic signs, but refused surgical operation and are
followed with symptomatic treatment.
Three hundred twenty-one patients (96.7%) were treated with
benznidazole. Eleven patients (3.3%) were not treated because of
refusal of treatment, or previous treatment in the country of origin.
Patients who presented at least one adverse effect were 89/321
(27.7%). In particular, 70 patients (21.8%) reported mild adverse
effects, such as mild allergic skin reaction (54/70 patients),
gastrointestinal adverse events (5/70), neurological or general
adverse effects (headache, somnolence, weakness and arthromyal-
gia)(8/70), transaminase elevation (3/70); nineteen patients (5.9%)
reported severe adverse effects, such as severe allergic skin
reactions (7/19), peripheral neuropathy (6/19), leucopoenia
(WBC ,2500 cells/mL) (6/19). Patients who completed the
treatment were 267/321 (83.2%). Among the 54 patients who
had to stop the treatment, 19 had reported severe adverse effects,
26 mild allergic skin reactions, 3 gastrointestinal adverse effects, 5
neurological adverse effects, one had transaminase elevation. Two
patients received nifurtimox as a second choice: one patient
completed the therapy, the other one had to stop because of
toxicity.
Discussion
In our study we present 332 patients with CD who attended our
Centre in a 9-year period. This represents the largest cohort of T.
cruzi infected patients reported in Italy, taking into account that
currently around 360 patients have been diagnosed and eventually
treated in the whole of Italy (Non Endemic Country – ‘‘NEC’’
Initiative; meeting in Florence 2013).
Unfortunately, it has been estimated that around 9200 cases
may be present in Italy [5], therefore an improvement of the
access to diagnosis and cure is strongly needed. Lack of awareness
both in the medical community and also in the majority of Latin
American immigrants, scarceness of specialized facilities where
screening tests are available, absence of specific National
guidelines/recommendations are some of the main obstacles to
reach this goal.
The majority of our patients (97.3%) came from Bolivia; this is
due both to the fact that Bolivia is the country with the highest
prevalence worldwide, and that our screening program was
implemented with the Bolivian community in Northern Italy.
The mean age was 41.8 years and 73.9% of the patients were
women: these data reflect the profile of immigrants from South
America, who are mostly young women working as caregivers for
elderly Italians.
We had 4 patients under immunosuppressant therapies, but
fortunately none of them presented reactivation of CD; on the
other hand, the patient with AIDS had a reactivation of CD and
needed heart transplantation. In this regard, the clinicians should
consider the risk of reactivation of CD in immunosuppressed
patients, with higher parasitaemia and life threatening manifesta-
tions, such as meningoencephalitis and myocarditis [17].
We found 13.2% of patients with cardiac involvement (cardiac
and mixed form): this percentage is considerably lower than the
data reported by the main case series of chronic CD patients in
Table 1. Characteristics of the 332 patients with Chagas
disease.
Age, years (mean) 41,8 (range 11–71)








Co-morbidities causing immunosuppression 5 (1.5%)
History of rural environments 205 (61.7%)
History of mud houses 243 (73.2%)
History of blood transfusion in endemic countries 23 (6.9%)
Time since arrival to Italy (years, mean) 6.9 (range 1–25)
doi:10.1371/journal.pntd.0003361.t001
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endemic areas [18–26] (mean 35.3%, range 20.3%–52.1%), but
also lower than main case series in Europe (mean 24.5%, range
19.9%–49.0%) [16,27–31]. The differences between endemic
countries and Europe are probably due to the fact that in endemic
areas symptomatic patients with cardiac involvement attend health
centers more often than asymptomatic subjects, and that most
Latin American immigrants are on average younger than the
resident population. However, our rate of cardiac involvement is
even lower than the ones reported by other European case series.
The main reasons could be due to differences in the origin of the
study populations, in the screening methods and classifications
criteria. For instance, we decided not to consider clinical
symptoms for the classification of heart disease but to rely only
on instrumental parameters, because symptoms are nonspecific
and hardly comparable [10]. Serological screening was offered to
all the members of the Bolivian community in Bergamo province,
therefore our data can be considered a more reliable picture of the
entire population (about 22% of the screened population resulted
positive for CD).
Also for gastrointestinal involvement we decided to classify the
patients without considering the symptoms. In fact, most signs and
symptoms of digestive involvement are non specific; moreover,
patients with CD can present digestive disorders unrelated to this
infection [13]. Our rate of patients with digestive involvement
(around 20%) is similar to the ones reported by the main case
series of chronic CD patients in endemic areas [18–26] (mean
20.4%, range 9.5%–35.1%), but significantly higher than main
clinical series in Europe (mean 8.7%, range 0.7%–22%) [16,27–
31]. Dolichocolon and megacolon were the most frequent findings
while oesophagus alterations were found in a very small
percentage of patients. Our data are similar to the ones by
Salvador et al [17] and therefore we reached the same conclusions:
Fig. 1. Classification of the 332 patients into different categories of Chagas disease.
doi:10.1371/journal.pntd.0003361.g001
Table 2. Cardiac involvement in 332 patients with Chagas disease.
Findings Stages Patients %
Normal ECG, normal echocardiogram 0 288 86.8
Abnormal ECG findings, normal echocardiogram findings, no signs of CHF A 30 9.0
Abnormal ECG findings, abnormal echocardiogram findings with LVEF.45%, no signs of CHF B1 7 2.1
Abnormal ECG findings, abnormal echocardiogram findings with LVEF ,45%, no signs of CHF B2 2 0.6
Abnormal ECG findings, abnormal echocardiogram findings, compensated CHF C 4 1.2
Abnormal ECG findings, abnormal echocardiogram findings, refractory CHF D 1 0.3
doi:10.1371/journal.pntd.0003361.t002
Chagas Disease in Italy
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colonic radiological evaluation is useful for every patient, while
systematic oesophageal assessment is probably not cost-effective in
asymptomatic patients. Perez Ayala et al [32] suggested that
oesophageal manometry may be more useful than barium swallow
for the detection of early oesophageal involvement, as previously
reported by Dantas [33]; he also postulated that early treatment
with benznidazole may offer similar benefits in gastro-intestinal
involvement as is reported in cardiomyopathy[34], but evidence is
scarce [32].
The treatment for CD includes only two drugs, nifurtimox and
benznidazole. The latter, in consideration of its better safety and
efficacy profile, is used as first line treatment [15]. However
benznidazole, too, can cause serious adverse events, moreover
efficacy data are based only on a few studies [34,35]. Although
more evidence is needed, we considered potential toxicity less
dangerous than the possible complications of the disease. We thus
treated almost all subjects with a positive serologic result (96.7%):
this percentage is higher if compared to other studies in non
endemic countries. In our series 27.7% of the patients reported
adverse effects (21.8% mild, and 5.9% severe). These rates are
lower than those (40.2%) reported by Carrilero et al [36] and
(52%) by Perez Ayala et al [16]. Patients who had to stop the
treatment were 16.8% in our series, 29.7% in the case series by
Perez Ayala et al, and 5.6% in that by Carrilero et al. However,
data are very heterogeneous and need a standardisation to be
correctly evaluated.
Some problems are still unsolved in Italy: the patients diagnosed
and treated so far are only a small proportion of the estimated
affected population and should be considered as a first step after
‘‘breaking the epidemiological silence’’ [6]. Considering that the
majority of patients are asymptomatic, public health measures for
the prevention of the transmission and improvement of the access
to diagnosis and treatment should be implemented.
Until now no case of transmission of CD through blood
transfusion or organ donation has been reported in Italy. One case
of fatal reactivation after a bone marrow transplantation
performed in Italy in an Argentinean girl was reported [37], as
well as one case of mother-to-child transmission (Non Endemic
Country – ‘‘NEC’’ Initiative; meeting in Florence 2013).
Unfortunately this issue has not yet been officially addressed in
our country, despite the profile of Latin American immigrants
resident in Italy, that is worrisome in relation to the possibility of
vertical transmission of CD. The only Italian Region that has
implemented an official screening program targeted to Latin
American pregnant women is Tuscany; in Bergamo area
(Lumbardy), too, a screening program to control vertical
transmission has been implemented since August, 2013. In the
next months Veneto Region, too, will implement a pilot screening
(Napoletano G, personal communication).
Conclusions
CD is an example of a new challenge of global health and
should be no longer perceived as an exotic disease [30], but one
Table 3. Electrocardiographic alterations in 44 patients with Chagas disease.
Findings Patients %
Bradycardia (,50 bpm) 11 25.0
Right bundle branch block 10 22.7
Low voltages 6 13.7
First-degree atrioventricular block 5 11.4
Pacemaker 5 11.4
Tachyarrhythmia 3 6.8
Right bundle branch block and hemiblock 2 4.5
Q waves suggestive of necrosis or T waves changes suggesting ischemia 2 4.5
doi:10.1371/journal.pntd.0003361.t003




dolichocolon: length from the anus to the transition to the descending colon.70 cm 33 9.9
megacolon: descending colon diameter.6,5 cm or ascending colon diameter.8 cm, or caecum diameter.12 cm 30 9.0
Oesophagogram
normal 328 98.8
group I: oesophagus with normal calibre but with slow contrast progression and small retention of contrast 1 minute after ingestion 3 0.9
group II: oesophagus with small to moderate dilatation and considerable radiological contrast retention 0 0
group III: hypotonic oesophagus with important dilatation and great retention of contrast 0 0
group IV: oesophagus elongated that lies over the diaphragm with great retention of contrast (dolico-megaoesophagus) 1 0.3
doi:10.1371/journal.pntd.0003361.t004
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that is currently present in Italy. Public health policies (with the
support of anthropologists) to reach migrants from Latin America
are urgently needed in order to plan appropriate screening
strategies to facilitate contacts with the communities of immigrants
[30], test risk groups and offer the treatment to the patients with
the infection.
Official European guidelines for CD management are still
lacking (the Spanish ones are commonly followed [9,13]).
Moreover, different classifications (for cardiac and digestive
involvement) are being used internationally. Efforts are necessary
in order to uniform management strategies and classification
criteria. Moreover, up to now, we do not have any evidence on the
disease evolution in non endemic countries where vectorial re-
infection is not possible and where there are different life styles and
comorbidities.
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